Amedisys (NASDAQ:AMED) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report released on Monday. The firm currently has a $62.00 target price on the health services provider’s stock. Zacks Investment Research‘s target price suggests a potential upside of 11.05% from the stock’s previous close.

According to Zacks, “Over the past year, Amedisys has been trading above the broader industry. The company is currently exploring new opportunities in both Home Health and Hospice. At the Home Health division, the company witnessed a decline in Medicare revenues, while there was an improvement in non-Medicare revenues. At the Hospice division, the company registered strong growth across all segments. A favorable demographic trend and strategic acquisitions bode well for the company. On the flip side, escalating operating expenses and declining gross margin continue to raise concerns. Also, an intense competitive landscape and regulatory concerns continue to pose challenges in the home health and hospice industry.”

Several other equities research analysts also recently commented on AMED. Robert W. Baird reiterated a “hold” rating and set a $50.00 target price on shares of Amedisys in a report on Wednesday, October 4th. Mizuho reiterated a “buy” rating and set a $65.00 target price (up from $55.00) on shares of Amedisys in a report on Wednesday, November 8th. BidaskClub downgraded Amedisys from a “sell” rating to a “strong sell” rating in a report on Thursday, January 11th. Benchmark reiterated a “hold” rating on shares of Amedisys in a report on Thursday, November 9th. Finally, Craig Hallum reiterated a “buy” rating and set a $68.00 target price (up from $55.00) on shares of Amedisys in a report on Thursday, November 9th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and seven have issued a buy rating to the company. The company has an average rating of “Hold” and a consensus price target of $61.09.

Amedisys (NASDAQ:AMED) opened at $55.83 on Monday. The company has a market capitalization of $1,919.80, a PE ratio of 44.66, a PEG ratio of 1.18 and a beta of 0.71. The company has a quick ratio of 1.33, a current ratio of 1.33 and a debt-to-equity ratio of 0.16. Amedisys has a twelve month low of $43.48 and a twelve month high of $65.91.

Amedisys (NASDAQ:AMED) last released its quarterly earnings data on Tuesday, November 7th. The health services provider reported $0.56 EPS for the quarter, topping analysts’ consensus estimates of $0.54 by $0.02. The company had revenue of $380.20 million for the quarter, compared to the consensus estimate of $384.59 million. Amedisys had a return on equity of 14.68% and a net margin of 2.88%. The company’s quarterly revenue was up 5.1% compared to the same quarter last year. During the same period last year, the business posted $0.36 EPS. equities research analysts anticipate that Amedisys will post 2.24 earnings per share for the current year.

Hedge funds and other institutional investors have recently modified their holdings of the business. Riverhead Capital Management LLC grew its stake in Amedisys by 75.5% during the 2nd quarter. Riverhead Capital Management LLC now owns 1,931 shares of the health services provider’s stock valued at $121,000 after purchasing an additional 831 shares in the last quarter. Federated Investors Inc. PA grew its stake in Amedisys by 2.3% during the 2nd quarter. Federated Investors Inc. PA now owns 1,929 shares of the health services provider’s stock valued at $122,000 after purchasing an additional 44 shares in the last quarter. Quantitative Systematic Strategies LLC acquired a new stake in Amedisys during the 3rd quarter valued at approximately $205,000. Amalgamated Bank acquired a new stake in Amedisys during the 2nd quarter valued at approximately $246,000. Finally, NorthCoast Asset Management LLC acquired a new stake in Amedisys during the 3rd quarter valued at approximately $262,000. Hedge funds and other institutional investors own 94.70% of the company’s stock.

WARNING: This piece of content was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece of content on another domain, it was copied illegally and reposted in violation of US and international copyright and trademark legislation. The original version of this piece of content can be viewed at https://www.thecerbatgem.com/2018/01/24/amedisys-amed-upgraded-at-zacks-investment-research.html.

About Amedisys

Amedisys, Inc is a healthcare services company. The Company’s segments are Home Health, Hospice, Personal Care and Other. The Company is a provider of home health, hospice and personal care services. As of December 31, 2016, the Company owned and operated 327 Medicare-certified home healthcare centers, 79 Medicare-certified hospice care centers and 14 personal-care care centers in 34 states within the United States and the District of Columbia.

Get a free copy of the Zacks research report on Amedisys (AMED)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Amedisys (NASDAQ:AMED)

Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.